{"id":"NCT00551616","sponsor":"HRA Pharma","briefTitle":"Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency Contraception","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-04","primaryCompletion":"2009-04","completion":"2009-04","firstPosted":"2007-10-31","resultsPosted":"2022-03-16","lastUpdate":"2022-05-03"},"enrollment":2221,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Contraception"],"interventions":[{"type":"DRUG","name":"CDB-2914","otherNames":[]},{"type":"DRUG","name":"Levonorgestrel","otherNames":[]}],"arms":[{"label":"CDB-2914","type":"EXPERIMENTAL"},{"label":"Levonorgestrel","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to assess the safety and efficacy of CDB-2914 in comparison to levonorgestrel for preventing pregnancy up to 5 days after unprotected sexual intercourse.","primaryOutcome":{"measure":"Number of Participants With Pregnancy","timeFrame":"Within 72 hours of unprotected Intercourse","effectByArm":[{"arm":"CDB-2914","deltaMin":20,"sd":null},{"arm":"Levonorgestrel","deltaMin":30,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":11},"locations":{"siteCount":33,"countries":["United States","Ireland","United Kingdom"]},"refs":{"pmids":["20116841"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":1104},"commonTop":["Headache","Dysmenorrhoea","Nausea","Abdominal pain","Dizziness"]}}